RFK Jr.'s vaccine panel votes no on thimerosal. What is that and why is there controversy?
A key vaccine committee, newly appointed by Health and Human Services Secretary Robert F. Kennedy Jr., voted against recommending certain vaccines that contain a preservative long targeted by anti-vaccine advocates despite broad scientific consensus on its safety.
The call against the preservative, called thimerasol, was first presented by Lyn Redwood, former leader of Children's Health Defense, an anti-vaccine group founded by Kennedy, during a June 26 meeting for the Advisory Committee on Immunization Practices.
She argued that thimerosal is a neurotoxin and the panel should recommend only thimerosal-free flu vaccines for all pregnant women, infants and children. The panel also voted the same recommendation for adults.
Health experts were shocked to see that thimerosal, a preservative that has largely been phased out of U.S. vaccines, was on the ACIP agenda when it was posted on the Centers for Disease Control and Prevention website June 25.
Before the vote, panel members argued back and forth on whether thimerosal is safe, despite scientific literature showing no link between vaccines containing the preservative and autism or other neurodevelopmental disorders.
The eight new ACIP members met for the first time June 25. Kennedy fired all 17 original members of the committee on June 9 and appointed its new members, which included some vaccine skeptics, a few days later.
Preservatives, such as thimerosal, are compounds that kill or prevent the growth of microorganisms, such as bacteria and fungi, according to the FDA. However, improvements in manufacturing technology have decreased the need to add such preservatives.
A CDC briefing document compiled by staff and posted on its website noted that in the 2024-2025 season, 96% of all influenza vaccines in the U.S. were thimerosal-free.
The agency says it has actively addressed the issue of thimerosal as a preservative and its use has significantly declined over the decades. All vaccines routinely recommended for children 6 and under are available in versions that don't contain thimerosal, the FDA said.
While most vaccines don't contain thimerosal, the agency states that 'a robust body of peer-reviewed, scientific studies conducted in the United States and countries around the world support the safety of thimerosal-containing vaccines.'
'The scientific evidence collected over the past 20+ years does not show any evidence of harm, including serious neurodevelopmental disorders, from use of thimerosal in vaccines,' the FDA says on its website.
Contributing: Julie Steenhuysen and Michael Erman, Reuters
Adrianna Rodriguez can be reached at adrodriguez@usatoday.com.
This article originally appeared on USA TODAY: RFK, Jr. ACIP panel votes on vaccines with thimerosal: What is that?
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
23 minutes ago
- Politico
Kennedy's vaccine panel met for the first time. Here's what to know.
ATLANTA — The first meeting of Health Secretary Robert F. Kennedy Jr.'s handpicked vaccine advisers concluded Thursday — setting the stage to change the childhood vaccine schedule and voting to stop recommending flu shots with an additive that has long been a target of the anti-vaccine movement. The meeting offered a glimpse into how the new Advisory Committee on Immunization Practices will operate — and how federal vaccine policy is beginning to reflect Kennedy's personal views. Earlier this month, he fired 17 members of the panel and replaced them with eight members, several of whom have histories of vaccine skepticism. One resigned before the meeting began, leaving seven members. HHS spokesperson Andrew Nixon told reporters that 'the members of the committee are respected experts who take their responsibility to public health seriously' and who 'deliver recommendations rooted in data and medical integrity.' Here are the takeaways from the two-day meeting at CDC headquarters in Atlanta: Its agenda was Kennedy's The panel voted Thursday to stop recommending that anyone get a flu vaccine that contains thimerosal, a preservative that Kennedy has long wanted gone. Kennedy, in 2014, wrote a book about thimerosal, arguing that it likely causes autism and should be banned. But many public health agencies have long considered it to be safe — including the CDC, according to its website. 'Scientists have been studying the use of thimerosal in vaccines for many years. They haven't found any evidence that thimerosal causes harm,' the website reads. The CDC director usually needs to endorse the recommendations before they are official. But Kennedy will likely be the one to endorse these recommendations because there is currently no CDC director or acting director. What it means: If endorsed, the new recommendations will mark one of the most prominent examples of Kennedy's own views reflected in U.S. vaccine policy since becoming HHS secretary. 'Even though this move only affects a small portion of the flu vaccine supply and likely won't impact access in the US this season, the symbolism is powerful. It signals that falsehoods may have a place in shaping vaccine policy in America,' Katelyn Jetelina, an epidemiologist who has consulted for the CDC, told POLITICO. 'The ripple effects could undermine trust in vaccines, vaccine access globally and weaken pandemic preparedness.' Thimerosal continues to be used as a preservative in some multi-dose vaccine vials to inhibit germ growth. But its use in FDA-licensed flu vaccines has declined over the last 25 years as manufacturers reformulated their products and shifted to single-use vials. Most of those contain little or no thimerosal, according to the CDC. That shift was tied to concerns raised in the late 1990s and early 2000s that thimerosal, a mercury-containing compound, could be linked to autism in children. In 1999, the FDA and CDC announced plans to work with manufacturers to reduce or remove thimerosal from vaccines as a precaution. The preservative was largely removed from pediatric vaccines by 2001. One member's pushback The panel's lone pediatrician, Dartmouth's Dr. Cody Meissner, was the only voting member to push back on views presented that contradicted scientific consensus, a development that encouraged some public health experts who were otherwise troubled by the meeting. 'He's dealt with vaccine-preventable diseases. He's talked to parents about vaccines, so I thought he was generally a voice of reason,' said Dr. Paul Offit, a pediatrician who serves on the FDA's external vaccine panel. What it means: It remains to be seen how Meissner will approach controversial topics at future meetings. He's also publicly agreed with Kennedy's move to pull the Covid-19 vaccine recommendation for pregnant women despite ample evidence of its benefits. Meissner told Reuters in May he thought politics had caused officials to overemphasize the importance of Covid vaccination for pregnant women and young children. Offit and former federal health officials applauded his participation and his defense of science. Meissner was critical of the American Academy of Pediatrics for not participating in the meeting. Several professional groups send liaisons to ACIP meetings to weigh in, though they don't have voting privileges. 'It's somewhat childish for them not to appear,' Meissner said near the end of the meeting Thursday. 'It's dialogue that leads to the best recommendations for the use of vaccines.' Dr. Sean O'Leary, the AAP's committee liaison, defended the organization's decision to not participate, saying ACIP 'has drifted so far from its long standing focus on science, evidence, public health.' 'When that focus returns, we will, too,' he said. More scrutiny of vaccines is ahead The committee's agenda items in the months ahead signal that Thursday's thimerosal votes were just the beginning of policy shifts that could affect vaccine access in the U.S. ACIP Chair Martin Kulldorff, an epidemiologist and former Harvard Medical School professor, said Wednesday the panel will review childhood vaccines and shots not studied in more than seven years, opening up the possibility of significant changes to the pediatric schedule. And he said Thursday the panel may consider at its next meeting advising against use of a combination shot known as MMRV against measles and chickenpox to children under 4. The CDC currently recommends that children under 2 get their first measles, mumps and rubella vaccine and varicella vaccine as separate shots because of an elevated risk with the MMRV shot of febrile seizure, which is common in young children but doesn't cause permanent harm. Why it matters: The thimerosal vote and the potential MMRV recommendation change wouldn't affect a wide swath of the population, given ample supply of alternatives. But those shifts could disproportionately impact vulnerable groups that already face issues accessing health care, like rural state residents and low-income families because they are more likely to get flu shots from wide-scale vaccination drives, public health experts say — not to mention plant the seeds for distrust in other vaccines. Anti-vaccine activists have long alleged links between vaccines and autism. They've theorized that thimerosal, the number of vaccines given to young children and post-immunization fevers could all contribute to the rise in diagnoses, despite peer-reviewed science finding no connections. While the CDC says just 4 percent of the U.S. flu vaccine supply last season contained thimerosal, scientists worry that the ACIP votes will reinvigorate unfounded worries about the ingredient that could generally suppress vaccine confidence — not to mention create access issues for the sliver of the population served by those multi-dose vials. The MMRV vaccine is also not widely used in children under 4. 'The goal was to scare people … the goal was to say, 'Here, look, these companies are putting things in vaccines that are dangerous,'' Offit said.
Washington Post
37 minutes ago
- Washington Post
Oklahoma seeks to exclude soda, candy from food stamp purchases
Oklahoma Gov. Kevin Stitt said Thursday the state is seeking federal permission to exclude soft drinks and candy from the list of items that can be purchased under the benefit for low-income Americans long known as food stamps. Stitt made the announcement during an event at the Capitol with U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. as part of the 'Make America Healthy Again' initiative.
Yahoo
38 minutes ago
- Yahoo
CVS unit ordered to pay $95 million in Medicare whistleblower lawsuit
By Jonathan Stempel (Reuters) -CVS Health's pharmacy benefit manager unit must pay the U.S. government $95 million after a federal judge found it overcharged Medicare for prescription drugs. Chief Judge Mitchell Goldberg in Philadelphia ordered the payment by CVS Caremark on Wednesday, following an eight-day non-jury trial in March in the whistleblower case. Goldberg will decide after further briefing whether to triple the award to $285 million under the federal False Claims Act. The case was brought in 2014 by Sarah Behnke, a former head actuary for Medicare Part D at Aetna. Behnke accused CVS Caremark of having since 2010 caused health insurers, such as Aetna, to submit inflated claims to the Centers for Medicare and Medicaid Services (CMS), while pharmacies such as Rite Aid and Walgreens were paid less. CVS bought Aetna in 2018. Despite ruling for CVS Caremark on some claims, Goldberg concluded in a 105-page decision that the unit knew it was managing drug prices in a manner that boosted margins, and therefore profit. "Although it is true that Aetna had the ultimate responsibility to submit the claims, I disagree that this responsibility absolves Caremark of culpability," Goldberg wrote. CVS, based in Woonsocket, Rhode Island, said on Thursday it was disappointed in the rulings against CVS Caremark. The False Claims Act lets whistleblowers sue on behalf of the government and share in recoveries, typically 15% to 30%. Though not directly involved in Behnke's case, the federal government said in an October 2023 court filing it had a strong interest in ensuring that Medicare Part D did not pay inflated drug prices, and information reported by plan sponsors and pharmacy benefit managers to CMS reflects the true costs. The case is US ex rel Behnke v CVS Caremark Corp et al, U.S. District Court, Eastern District of Pennsylvania, No. 14-00824. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
